Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 known ✓ | P47900 | 9/20 | 0.53 |
| ▸ | P2RY2 known ✓ | P41231 | 3/20 | 0.48 |
| ▸ | ADORA1 known ✓ | P30542 | 1/20 | 0.47 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.47 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.47 |
| ▸ | P2RY11 | Q96G91 | 3/20 | 0.53 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.51 |
| ▸ | BLM | P54132 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.48 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.48 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.48 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19326673 | 1.00 | P2RY1 (0.53) | P2RY1P2RY11ENPP1BLMTSHR | |
| SCHEMBL16130072 | 0.85 | P2RY1 (0.63) | P2RY1P2RY11P2RY2SRCSMN1; SMN2 | |
| SCHEMBL17481937 | 0.84 | P2RY1 (0.52) | P2RY1P2RY11ENPP1P2RY2SRC | |
| SCHEMBL16130074 | 0.83 | P2RX3 (0.64) | P2RY1P2RY11P2RY2SRCSMN1; SMN2 | |
| SCHEMBL16094147 | 0.82 | P2RX3 (0.63) | P2RY1P2RY11P2RY2SRCSMN1; SMN2 | |
| Adenosine Triphosphate SCHEMBL29576424 | 0.80 | P2RY1 (0.80) | P2RY1P2RY11ENPP1BLMTSHR | |
| Adenosine Triphosphate SCHEMBL29905572 | 0.80 | P2RY1 (0.80) | P2RY1P2RY11ENPP1BLMTSHR | |
| Adenosine Triphosphate SCHEMBL193646 | 0.80 | P2RY1 (0.80) | P2RY1P2RY11ENPP1BLMTSHR | |
| Adenosine Triphosphate SCHEMBL3134374 | 0.80 | P2RY1 (0.79) | P2RY1P2RY11ENPP1BLMTSHR | |
| Adenosine Triphosphate SCHEMBL31149196 | 0.80 | P2RY1 (0.79) | P2RY1P2RY11ENPP1BLMTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250257090-A1 | Ribonucleic Acids With 4'-Thio-Modified Nucleotides and Related Methods | TRANSLATE BIO, INC. (US) | 2025-08-14 | — | — | US | disclosed |
| US-12247046-B2 | Ribonucleic acids with 4′-thio-modified nucleotides and related methods | TRANSLATE BIO, INC. (US) | 2025-03-11 | — | — | US | disclosed |
| US-20230192753-A1 | RIBONUCLEIC ACIDS WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS | RANA THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-11447520-B2 | Ribonucleic acids with 4′-thio-modified nucleotides and related methods | TRANSLATE BIO, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20210009629-A1 | RIBONUCLEIC ACIDS WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS | TRANSLATE BIO, INC. | 2021-01-14 | — | — | US | disclosed |
| EP-3750903-A1 | RIBONUCLEIC ACIDS WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS | Translate Bio, Inc. (US) | 2020-12-16 | — | — | EP | disclosed |
| US-10822368-B2 | Ribonucleic acids with 4′-thio-modified nucleotides and related methods | TRANSLATE BIO, INC. (US) | 2020-11-03 | — | — | US | disclosed |
| EP-3301102-B1 | RIBONUCLEIC ACIDS WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS | TRANSLATE BIO INC (US) | 2020-04-15 | — | — | EP | disclosed |
| US-20190263850-A1 | RIBONUCLEIC ACIDS WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS | TRANSLATE BIO, INC. | 2019-08-29 | — | — | US | disclosed |
| US-10266559-B2 | Ribonucleic acids with 4′-thio-modified nucleotides and related methods | TRANSLATE BIO, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| EP-3301102-A1 | RIBONUCLEIC ACIDS WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS | Translate Bio, Inc. (US) | 2018-04-04 | — | — | EP | disclosed |
| US-20160031928-A1 | RIBONUCLEIC ACIDs WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS | TRANSLATE BIO, INC. | 2016-02-04 | — | — | US | disclosed |
| EP-2970351-A1 | RIBONUCLEIC ACIDs WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS | Shire Human Genetic Therapies, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014152513-A1 | RIBONUCLEIC ACIDs WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250257090-A1 | Ribonucleic Acids With 4'-Thio-Modified Nucleotides and Related Methods | RNMT, RNGTT, NSUN3 | P2RY1 1511/4885P2RY2 1784/4885ADORA1 821/4885 |
| US-10822368-B2 | Ribonucleic acids with 4′-thio-modified nucleotides and related methods | RNMT, RNGTT, NSUN3 | P2RY1 1529/4885P2RY2 1817/4885ADORA1 811/4885 |
| US-20190263850-A1 | RIBONUCLEIC ACIDS WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS | RNMT, RNGTT, NSUN3 | P2RY1 1511/4885P2RY2 1784/4885ADORA1 821/4885 |
| US-20210009629-A1 | RIBONUCLEIC ACIDS WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS | RNMT, RNGTT, NSUN3 | P2RY1 1511/4885P2RY2 1784/4885ADORA1 821/4885 |
| US-12247046-B2 | Ribonucleic acids with 4′-thio-modified nucleotides and related methods | RNMT, RNGTT, NSUN3 | P2RY1 1529/4885P2RY2 1817/4885ADORA1 811/4885 |
| US-20230192753-A1 | RIBONUCLEIC ACIDS WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS | RNMT, RNGTT, NSUN3 | P2RY1 1511/4885P2RY2 1784/4885ADORA1 821/4885 |
| US-20160031928-A1 | RIBONUCLEIC ACIDs WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS | RNMT, RNGTT, NSUN3 | P2RY1 1511/4885P2RY2 1784/4885ADORA1 821/4885 |
| US-11447520-B2 | Ribonucleic acids with 4′-thio-modified nucleotides and related methods | RNMT, RNGTT, NSUN3 | P2RY1 1529/4885P2RY2 1817/4885ADORA1 811/4885 |
| US-10266559-B2 | Ribonucleic acids with 4′-thio-modified nucleotides and related methods | RNMT, RNGTT, NSUN3 | P2RY1 1529/4885P2RY2 1817/4885ADORA1 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.